Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Tax Provisions (2018 - 2026)

10x Genomics' Tax Provisions history spans 8 years, with the latest figure at $1.1 million for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 63.43% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 26.18% decrease, with the full-year FY2025 number at $3.6 million, down 26.18% from a year prior.
  • Tax Provisions hit $1.1 million in Q4 2025 for 10x Genomics, up from -$733000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for TXG hit a ceiling of $2.5 million in Q2 2025 and a floor of -$733000.0 in Q3 2025.
  • Historically, Tax Provisions has averaged $1.2 million across 5 years, with a median of $1.1 million in 2023.
  • Biggest five-year swings in Tax Provisions: soared 259.27% in 2022 and later crashed 155.74% in 2025.
  • Tracing TXG's Tax Provisions over 5 years: stood at $2.5 million in 2021, then plummeted by 67.26% to $804000.0 in 2022, then skyrocketed by 192.79% to $2.4 million in 2023, then tumbled by 72.47% to $648000.0 in 2024, then surged by 63.43% to $1.1 million in 2025.
  • Business Quant data shows Tax Provisions for TXG at $1.1 million in Q4 2025, -$733000.0 in Q3 2025, and $2.5 million in Q2 2025.